Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

98.34
+0.29000.30%
Post-market: 98.340.00000.00%19:30 EDT
Volume:398.38K
Turnover:39.28M
Market Cap:6.39B
PE:-6.98
High:99.69
Open:97.84
Low:97.47
Close:98.05
52wk High:130.00
52wk Low:63.23
Shares:64.93M
Float Shares:56.42M
Volume Ratio:0.87
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0800
EPS(LYR):-0.4700
ROE:-702.97%
ROA:-6.79%
PB:-612.69
PE(LYR):-209.23

Loading ...

Mirum Pharmaceuticals Inc - Pre-Nda Meeting for Volixibat in Psc Scheduled With FDA Summer 2026; Nda Submission Planned H2 2026

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals Inc - Volixibat Safety Profile Consistent With Ibat Inhibition; Mainly Gi Events and Elevated Liver Parameters

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals Inc - Volixibat Shows 2.72 Point Reduction in Pruritus, 1.64 Point Placebo-Adj (P<0.0001)

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals Inc - Expects Topline Data From Vantage Phase 2B Study of Volixibat in PBC in Q1 2027

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals updates financial calendar, sets quarterly results conference call

Reuters
·
Apr 30

Mirum Pharmaceuticals Inc : Stifel Raises Target Price to $130 From $125

THOMSON REUTERS
·
Apr 29

Mirum Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 28

Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright

TIPRANKS
·
Apr 27

Mirum Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $150 From $130

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Inc : Baird Raises Target Price to $112 From $95

THOMSON REUTERS
·
Apr 27

Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study

TIPRANKS
·
Apr 27

BUZZ-Mirum Pharma rises as hepatitis delta drug hits main goal

Reuters
·
Apr 27

Mirum says brelovitug meets primary endpoint in Phase 2b AZURE-1 HDV trial

Reuters
·
Apr 27

Mirum Pharmaceuticals Inc - Announces Primary Endpoint Met in Phase 2B Azure-1 Study of Brelovitug

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Inc - Primary Endpoint Achieved in Both Dose Arms at Week 24

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Inc - Topline Phase 3 Data From Azure-1 and Azure-4 Expected in H2 2026

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2B Portion of the Azure-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Inc: Favorable Safety and Tolerability Profiles Observed

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 24

Mirum Pharmaceuticals Price Target Maintained With a $132.00/Share by Citizens

Dow Jones
·
Apr 21